Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conferen...
Aerovate Therapeutics, Inc. (AVTE)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension. “We look forward to presenting baseline characteristics of the Phase 2b portion of the IMPAHCT trial in our poster presentation at the upcoming ATS conference in May,” said Tim Noyes, Chief Executive Officer at Aerovat
Show less
Read more
Impact Snapshot
Event Time:
AVTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVTE alerts
High impacting Aerovate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AVTE
News
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "outperform" rating re-affirmed by analysts at Wedbush.MarketBeat
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $35.00 price target on the stock.MarketBeat
- Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsGlobeNewswire
- Aerovate Therapeutics, Inc. (NASDAQ: AVTE) had its "buy" rating re-affirmed by analysts at Jefferies Financial Group Inc.. They now have a $65.00 price target on the stock, up previously from $21.00.MarketBeat
AVTE
Earnings
- 11/13/23 - Miss
AVTE
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- AVTE's page on the SEC website